Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Newron Pharmaceuticals SpA ( (CH:NWRN) ) just unveiled an announcement.
Newron Pharmaceuticals has announced the US launch of its global Phase III clinical study, ENIGMA-TRS 2, to evaluate Evenamide as an add-on therapy for treatment-resistant schizophrenia (TRS). This study, involving at least 400 patients, aims to establish Evenamide as the first approved add-on therapy for TRS, addressing a significant unmet medical need for patients who do not respond to existing antipsychotics. The study’s results, expected in late 2026, could significantly impact Newron’s market positioning and offer new hope for TRS patients worldwide.
The most recent analyst rating on (CH:NWRN) stock is a Buy with a CHF22.00 price target. To see the full list of analyst forecasts on Newron Pharmaceuticals SpA stock, see the CH:NWRN Stock Forecast page.
More about Newron Pharmaceuticals SpA
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company headquartered in Bresso near Milan, Italy, focused on developing innovative therapies for central and peripheral nervous system disorders. The company specializes in neuroscience-based therapies and is currently advancing its lead drug candidate, Evenamide, a first-in-class glutamate modulator, through the global ENIGMA-TRS Phase III development program for treatment-resistant schizophrenia.
YTD Price Performance: 104.25%
Average Trading Volume: 134,141
Technical Sentiment Signal: Buy
Current Market Cap: CHF364.9M
For detailed information about NWRN stock, go to TipRanks’ Stock Analysis page.